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Several challenges needs to addressed before a gene 
expression profile can be approved as a predictive biomarker 
by regulatory bodies like the European Medicines Agency 
(EMA) and the US Food and Drug Administration (FDA). In an 
ongoing trial, EORTC-1219 (ClinicalTrials.gov ID: 
NCT01880359), a 15-gene hypoxia profile (1,2) is being tested 
prospectively. One of the primary aims of the study is to 
provide data for regulatory approval of the gene profile as an 
accompanying biomarker for the use of the hypoxia modifier 
Nimorazole. 
The development and ongoing validation of this 15-gene 
profile will be used as a general example of the challenges 
for implementing gene expression profiles in PRO. Different 
strategies for identification of relevant gene expression 
profiles will be discussed together with the challenges of 
validating the predictive value of a gene expression profile. 
The requirements for a quick and robust test for the gene 
expression profile working on simple routine FFPE (formalin-
fixed, paraffin-embedded) sections will also be discussed. 
Finally, some of the regulatory and patent issues related to 
gene expression profiles will be commented upon. 
1. Toustrup et al. Cancer Res. 71(17):5923-31, 2011. 
2. Toustrup et al. Radiother Oncol 102(1):122-9, 2012. 
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A key challenge in radiotherapy is to maximise radiation 
doses to cancer while minimising damage to surrounding 
healthy tissues. As toxicity in a minority of patients limits the 
doses that can be safely given to the majority, there is 
interest in developing a test to measure an individual’s 
radiosensitivity before treatment and predict their likelihood 
of developing toxicity. A biomarker that predicts a cancer 
patient’s risk of toxicity could be used to personalise dose 
prescriptions or to offer alternative treatments. Many 
approaches have been studied to measure radiosensitivity. 
The development of omics technologies underpinned genome 
wide association studies (GWAS) attempting to identify 
genetic variants reported as single nucleotide polymorphisms 
(SNPs). The advantages of the approach include: a genetic 
test will be easier to implement clinically than a functional 
assay; a genetic test will not suffer from the poor 
reproducibility associated with some radiosensitivity testing 
methods; and SNPs are the most common type of genetic 
variation and so easiest to identify. Omics technologies offer 
promise, but to have an impact on radiotherapy practice 
research must identify biomarkers that replicate across 
cohorts. Robust replication needs big data, which is only 
possible with large collaborative efforts. The need for big 
data was addressed by establishing an international 
Radiogenomics Consortium. Achievements of the consortium 
include: pooling cohorts to increase statistical power and 
identify definitively whether individual SNPs are associated 
with risk of toxicity; producing guidelines to improve the 
reporting of radiogenomics studies; identifying approaches 
for analysing data from heterogeneous cohorts involving 
different toxicity reporting scales and treatment regimens; 
and establishing studies collecting standardised data to 
improve our ability to detect more SNPs. Work over the past 
three years showed it is possible to pool heterogeneous 
cohorts and has identified several SNPs associated with risk 
of toxicity. Large collaborative projects in the cancer pre-
disposition field involving analysis of ~100,000 participants 
shows that sufficient SNPs can be identified to generate a 
polygenic risk profile for clinical implementation. For 
example, men in the top 1% of the distribution of a 74-SNP 
polygenic risk score have a 4.7 fold increased risk of 
developing prostate cancer. Key challenges for the radiation 
oncology community are to collect the data in multiple 
cancers to identify enough SNPs to generate a polygenic risk 
profile and to increase understanding of the need for 
endpoint dependent versus independent profiles. 
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Personalized Radiation Oncology (PRO) integrating omics 
technology is a rapidly developing concept that will have an 
enormous impact on oncologic treatments and specifically 
radiation therapy in the near future. Tumor behaviour and 
outcomes related to oncologic treatments are related to 
several factors of which connections are nowdays poorly 
known. Different branches of medicine have developed their 
own lines of research which are sometimes difficult to be 
interpreted, difficult to be integrated with classical clinical 
factors and for these reasons, difficult to be applied in 
clinical practice. In clinical prediction and decision making 
process, results provided by omics are rarely used, whereas 
clinicians usually use clinical and imaging data for 
understanding tumor behaviour, predicting patients' 
outcomes and for choosing the the most suitable treatment. 
The clinical decision is usually based on general guidelines 
which extrapolate information from randomized clinical trial. 
Moreover independent factors derived from several RCT are 
used by the Radiation Oncologist to make his prevision on 
tumor behaviour and consequently to choose the „right 
treatment“ for a specific patient. Randomized clinical trials 
enclose patients with characteristics chosen beforehand and 
usually omics informations are rarely or never included. This 
lead to a potential missing of several information that could 
refine prediction and thus promote personalized treatments 
and to an erroneous outcomes prediction that can lead to un-
appropriate treatment decision for a specific patient. 
Integrative data analysis has the potential to correlate data 
of different origins (genetic, radiology, clinic...) with 
patient’s outcomes and to create a consistent dataset useful 
to obtain a trustful analysis for the Decision Support System. 
The DSS can easily be applied in clinical practice helping the 
Radiation Oncologist to utilize several information that 
otherwise would be excluded in the process of decision 
making. The possibility to predict the outcome for a certain 
patient in combination with a specific treatment with more 
accuracy, will lead to better identification of risk groups and 
thus better treatment decisions in individual patients, but it 
will also stimulate research focused on specific risk groups 
which try to find new treatment options or other 
combinations of treatment options for these subgroups. 
These treatments will be more personalized, which will not 
only save patients from unnecessary toxicity and 
inconvenience, but will also facilitate the choice of the most 
appropriate treatment . The resulting predictive models, 
based on patient features, enable a more patient specific 
selection from the treatment options menu and a possibility 
to share decisions with patients based on an objective 
evaluation of risks and benefits. Finally, considering the 
important role that predictive models could play in the 
clinical practice, clinicians must be aware of the limits of 
these prediction models. They need to be internally validated 
taking into account the quality of the collected data. An 
external validation of models is also essential to support 
general applicability of the prediction model. Therefore 
structural collaboration between different groups is crucial to 
generate enough anonymized large databases from patients 
included or not in clinical trials.  
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